Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation

Kidney International

Volumn 74, Issue 11, 2008, Pages 1420-1428

  Azzollini, Nadia ^a,b   Cugini, Daniela ^a,b,e   Cassis, Paola ^a,b   Pezzotta, Anna ^a,b   Gagliardini, Elena ^a   Abbate, Mauro ^a   Arduini, Arduino ^c   Peschechera, Alessandro ^d   Remuzzi, Giuseppe ^a,b   Noris, Marina ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Center for Research on Organ Transplantation   (Italy)

^c R and D Department   (Italy)

^d Sigma Tau SpA   (Italy)

^e MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Acute allograft rejection; Delayed graft function; Ischemia reperfusion; Kidney transplantation; Oxidative stress; Propionyl L carnitine

Indexed keywords

CYCLOSPORIN A; PROPIONYLCARNITINE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY INJURY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARNITINE; CYCLOSPORINE; GRAFT SURVIVAL; KIDNEY CORTEX NECROSIS; KIDNEY TRANSPLANTATION; NEUTROPHIL INFILTRATION; PROTECTIVE AGENTS; RATS; REPERFUSION INJURY; TRANSPLANTATION, HOMOLOGOUS;

EID: 56549096401     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.399     Document Type: Article

References (60)

1. Daly PJ, Power RE, Healy DA et al. Delayed graft function: a dilemma in renal transplantation. BJU Int 2005; 96: 498-501.
2. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827.
3. Quiroga I, McShane P, Koo DD et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689-1696.
4. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-1840.
5. Johnson KJ, Weinberg JM. Postischemic renal injury due to oxygen radicals. Curr Opin Nephrol Hypertens 1993; 2: 625-635.
6. Burke TJ, Schrier RW. Pathophysiology of cell ischemia. In: Schrier RW, Gottschalk CW (eds). Diseases of the Kidney. Little Brown and Co: Boston, 1997, pp 1013.
7. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62: 1539-1549.
8. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210.
9. Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH. Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant 2004; 9: 81-83.
10. Tahara M, Nakayama M, Jin MB et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 h of cold preservation and autotransplantation. Transplantation 2005; 80: 213-221.
11. Zahmatkesh M, Kadkhodaee M, Moosavi SM et al. Beneficial effects of MnTBAP, a broad-spectrum reactive species scavenger, in rat renal ischemia/reperfusion injury. Clin Exp Nephrol 2005; 9: 212-218.
12. Hines IN, Harada H, Wolf R et al. Superoxide and post-ischemic liver injury: potential therapeutic target for liver transplantation. Curr Med Chem 2003; 10: 2661-2667.
13. Simpson PJ, Mickelson JK, Lucchesi BR. Free radical scavengers in myocardial ischemia. Fed Proc 1987; 46: 2413-2421.
14. Bremer J. Carnitine - metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
15. Suzuki Y, Kamikawa T, Kobayashi A et al. Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts. Jpn Circ J 1981; 45: 687-694.
16. Davis EJ, Spydevold O, Bremer J. Pyruvate carboxylase and propionyl-CoA carboxylase as anaplerotic enzymes in skeletal muscle mitochondria. Eur J Biochem 1980; 110: 255-262.
17. Tassani V, Cattapan F, Magnanimi L et al. Anaplerotic effect of propionyl carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994; 199: 949-953.
18. Ferrari R, DeGiuli F. The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. J Card Fail 1997; 3: 217-224.
19. Caponnetto S, Canale C, Masperone MA et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994; 15: 1267-1273.
20. Paulson DJ, Traxler J, Schmidt M et al. Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc Res 1986; 20: 536-541.
21. Shug A, Paulson D, Subramanian R et al. Protective effects of propionyl-L-carnitine during ischemia and reperfusion. Cardiovasc Drugs Ther 1991; 5(Suppl 1): 77-83.
22. Ferrari R, Ceconi C, Cargnoni A et al. The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria. Cardiovasc Drugs Ther 1991; 5(Suppl 1): 57-65.
23. Signorelli SS, Fatuzzo P, Rapisarda F et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging 2006; 23: 263-270.
24. Mister M, Noris M, Szymczuk J et al. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 2002; 61: 1064-1078.
25. Lu CY, Penfield JG, Kielar ML et al. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int 1999; 55: 2157-2168.
26. Esterbauer H, Cheeseman KH, Dianzani MU et al. Separation and characterization of the aldehydic products of lipid peroxidation stimulated by ADP-Fe2+ in rat liver microsomes. Biochem J 1982; 208: 129-140.
27. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004; 101: 4003-4008.
28. De Greef KE, Ysebaert DK, Ghielli M et al. Neutrophils and acute ischemiareperfusion injury. J Nephrol 1998; 11: 110-122.
29. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
30. Welbourn CR, Goldman G, Paterson IS et al. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br J Surg 1991; 78: 651-655.
31. Cugini D, Azzollini N, Gagliardini E et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67: 1753-1761.
32. Sekido N, Mukaida N, Harada A et al. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654-657.
33. Hellberg PO, Kallskog TO. Neutrophil-mediated post-ischemic tubular leakage in the rat kidney. Kidney Int 1989; 36: 555-561.
34. Kelly KJ, Williams Jr WW, Colvin RB et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-1063.
35. Takada M, Nadeau KC, Shaw GD et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99: 2682-2690.
36. Souza DG, Cara DC, Cassali GD et al. Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat. Br J Pharmacol 2000; 131: 1800-1808.
37. Souza DG, Coutinho SF, Silveira MR et al. Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 2000; 403: 121-128.
38. Rouschop KM, Roelofs JJ, Claessen N et al. Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol 2005; 16: 2034-2043.
39. Linas SL, Whittenburg D, Parsons PE et al. Ischemia increases neutrophil retention and worsens acute renal failure: role of oxygen metabolites and ICAM 1. Kidney Int 1995; 48: 1584-1591.
40. Willinger CC, Schramek H, Pfaller K et al. Tissue distribution of neutrophils in postischemic acute renal failure. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 62: 237-243.
41. Paller MS. Effect of neutrophil depletion on ischemic renal injury in the rat. J Lab Clin Med 1989; 113: 379-386.
42. Thornton MA, Winn R, Alpers CE et al. An evaluation of the neutrophil as a mediator of in vivo renal ischemic-reperfusion injury. Am J Pathol 1989; 135: 509-515.
43. Arduini A, Gorbunov N, Arrigoni-Martelli E et al. Effects of L-carnitine and its acetate and propionate esters on the molecular dynamics of human erythrocyte membrane. Biochim Biophys Acta 1993; 1146: 229-235.
44. Hulsmann WC. Biochemical profile of propionyl-L-carnitine. Cardiovasc Drugs Ther 1991; 5(Suppl 1): 7-9.
45. Al-Majed AA, Sayed-Ahmed MM, Al-Omar FA et al. Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus. Clin Exp Pharmacol Physiol 2006; 33: 725-733.
46. Di Lisa F, Menabo R, Barbato R et al. Contrasting effects of propionate and propionyl-L-carnitine on energy-linked processes in ischemic hearts. Am J Physiol 1994; 267: H455-H461.
47. Calo LA, Pagnin E, Davis PA et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107: 54-60.
48. Gomez-Amores L, Mate A, Revilla E et al. Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 2006; 78: 1945-1952.
49. Ronca G, Ronca F, Yu G et al. Protection of isolated perfused working rat heart from oxidative stress by exogenous L-propionyl carnitine. Drugs Exp Clin Res 1992; 18: 475-480.
50. Packer L, Valenza M, Serbinova E et al. Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart. Arch Biochem Biophys 1991; 288: 533-537.
51. Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation. Arch Biochem Biophys 2004; 423: 12-22.
52. Bachmann S, Mundel P. Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis 1994; 24: 112-129.
53. Morrissey JJ, McCracken R, Kaneto H et al. Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 1994; 45: 998-1005.
54. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 1999; 56: 1967-1979.
55. Shoskes DA, Parfrey NA, Halloran PF. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation 1990; 49: 201-207.
56. Halloran PF, Hunsicker LG. Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115-120.
57. Yokoyama I, Uchida K, Kobayashi T et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8: 101-106.
58. Ojo AO, Wolfe RA, Held PJ et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974.
59. Dols JL, Sanders GT. Evaluation of the creatinine assay on the Reflotron analyser under centralized and non-centralized conditions. Eur J Clin Chem Clin Biochem 1993; 31: 359-366.
60. Aiello S, Cassis P, Cassis L et al. DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties. Transplantation 2007; 83: 474-484.